Publication: Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension
Loading...
Date
1987
Authors
Keith, lngegerd ; Will, James A. ; Huxtable, Ryan J. ; Weir, Kenneth
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The pathophysiologic mechanism by which
chronic hypoxia causes pulmonary hypertension is
unknown. If anti-platelet agents, or other pharmacologic
interventions, altered the pulmonary vascular changes
induced by hypoxia, information concerning the
pathogenesis of the pulmonary hypertension or the
potential therapeutic usefulness of the drugs might be
obtained. In Study 1, rats exposed to chronic hypobaric
hypoxia (P, = 520 mmHg) had a pulmonary arterial
medial thickness of 6.7 * 0.6 p compared to 4.1 + 0.2 p *
for control, normoxic rats (*p<0.05). Administration of
dipyridamole (2mg/kg/day), or sulfinpyrazone (1 1 mg/
kglday) in the drinking water reduced the medial
thickness to 5.0 2 0.3 p* and 5.4 2 0.5 p* respectively,
thus suggesting the possible involvement of platelets in
the response of the media to chronic hypoxia. In Study 2,
hypoxic rats treated with the calcium blocker,
flunarizine, were found to have less medial hypertrophy
than a control group of hypoxic rats. This observation
suggests that a decrease in transmembrane calcium flux
may also reduce medial hypertrophy.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.